Multiple Sclerosis 15 June 2004, vol. 10, no. Supplement 1, pp. 58-61(4)
Stüve O.; Kita M.; Pelletier D.; Fox R.J.; Stone J.; Goodkin D.E.; Zamvil S.S.
 Department of Neurology, University of California, San Francisco, CA, USA  Virginia Mason Multiple Sclerosis Center, Seattle, WA, USA  Department of Neurology, Mellen Center for MS, Cleveland Clinic Foundation, Cleveland, OH, USA  Multiple Sclerosis Therapeutics, Biogen, Cambridge, MA, USA
Mitoxantrone (Novantrone®) was the first drug approved in western Europe and North America for treatment of secondary progressive multiple sclerosis (SPMS) and progressive relapsing MS (PRMS).
Pharmacological properties of mitoxantrone, its role in SPMS, the study rational and design of an ongoing multi-centre, double blind, randomized, placebo-controlled phase 2 trial will be outlined in this article.